PR3-AAV Resilient Remission or PRRR

• Status: Not yet recruiting
• Trial end date: 2024-07-01

Summary

The purpose of this study is to evaluate the efficacy and safety of obinutuzumab for the treatment of proteinase 3 Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (PR3-AAV).

• Phase: Phase 2

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Obinutuzumab; Rituximab